Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zometa Label Adds Osteonecrosis Of The Jaw Precaution

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis sends "Dear Doctor" letter to notify oncologists, oral surgeons and urologists of the labeling change. The revised labeling recommends a dental examination prior to bisphosphonate treatment for at-risk patients.

You may also be interested in...



Zometa, Aredia "Dear Doctor" Letter Sent To Dentists On Jaw Osteonecrosis Risk

Novartis notifies 150,000 dental health professionals about the risk of osteonecrosis of the jaw in patients receiving intravenous bisphosphonates. FDA's Oncologic Drugs Advisory Committee had urged Novartis to notify dentists after an earlier "Dear Doctor" letter was sent to oncologists, hematologists, oral surgeons and urologists.

Zometa, Aredia "Dear Doctor" Letter Sent To Dentists On Jaw Osteonecrosis Risk

Novartis notifies 150,000 dental health professionals about the risk of osteonecrosis of the jaw in patients receiving intravenous bisphosphonates. FDA's Oncologic Drugs Advisory Committee had urged Novartis to notify dentists after an earlier "Dear Doctor" letter was sent to oncologists, hematologists, oral surgeons and urologists.

Novartis' Zometa Adds Warning On Renal Safety

Revised labeling recommends dosing should be decreased for patients with mild-to-moderate renal impairment, based on the patient's creatinine clearance levels. Novartis recommends identification and management of "factors predisposing of renal deterioration."

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel